Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability
A compound called ERX-41 targets a previously unrecognized vulnerability in difficult-to-treat types of cancer including triple-negative breast cancer. The compound will be studied as a drug for clinical translation.
Materials provided by University of Texas Health Science Center at San Antonio. Original written by Will Sansom. Note: Content may be edited for style and length.
Source link aaaaa